Latest Breaking News On - Meichiel keenan - Page 2 : comparemela.com

FibroGen Appoints Deyaa Adib, M D as Chief Medical Officer

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executiv.

Al qahirahCairo universityAl jizahUnited statesMeichiel keenanDavid deluciaDeyaa adibAstellas pharmaTriumvira immunologics incExchange commissionChina health authorityTufts university school of medicineCairo university school of medicineAmerican cancer instituteCorporate communicationsFibrogen inc

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

South koreaSouth africaUnited statesMeichiel keenanDavid deluciaAmerican society of hematology annual meetingPancreatic cancer action network phaseExchange commissionNational reimbursement drug listDrug administrationChina health authorityFibrogen incCorporate communicationsGen reports fourth quarterFull yearThane wettig

FibroGen, Inc : FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

FibroGen, Inc : FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South koreaSouth africaUnited statesDavid deluciaMeichiel keenanDrug administrationNational reimbursement drug listCorporate communicationsAmerican society of hematology annual meetingFibrogen incPancreatic cancer action network phaseChina health authorityExchange commissionThane wettigChief executive officerKey highlights

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting - FibroGen (NASDAQ:FGEN)

A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5%; p=0.047ǂ). Dr.

United statesSan diegoSouth africaDavid deluciaHeptinstallk leukMeichiel keenanMoshe mittelmanFibrogen incTel aviv sourasky medical centerExchange commissionCorporate communicationsChina health authorityAmerican society of hematologyAmerican societyAnnual meetingCalifornia december

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo . Dr. Moshe.

United statesSouth africaSan diegoDavid deluciaMoshe mittelmanDiego marinaHeptinstallk leukMeichiel keenanChina health authorityExchange commissionTel aviv sourasky medical centerCorporate communicationsGlobenewswire incAmerican society of hematologyFibrogen incAnnual meeting